Nasdaq
$9.75▲ 1.93%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $602.1MShares out 61.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
17- 3d agoPre-market26.10.22 20:158-KKey event#●●●#●●●#●●●
Sagimet Biosciences Inc.Bullish
Sagimet Biosciences updated its investor presentation on October 22, 2026, highlighting clinical progress for its lead drug candidate, denifanstat. The drug met all primary and secondary endpoints in a Phase 3 acne trial conducted by partner Ascletis in China, while the U.S. AURORA Phase 3 trial commenced with its first patient dosed in October 2026. As of June 30, 2026, the company held $257.6 million in cash, and with proceeds from a $115 million underwritten offering completed in September 2026, it expects to fund operations through mid-2029.…more
$9.75+1.93%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7After-hours26.10.08 07:28SCHEDULE 13GOwnership
Sagimet Biosciences Inc.
Commodore Capital LP and associated entities have filed a Schedule 13G regarding their stake in Sagimet Biosciences Inc. This filing formalizes the joint acquisition agreement and outlines the responsibilities for future reporting obligations among the filing parties.…more
$9.75+1.93%vs prev closeView filingShare - 10.1Pre-market26.10.01 07:00filed8-KKey event
Sagimet Biosciences Inc.
Sagimet Biosciences is raising $107.5 million in gross proceeds through an offering of 8,750,010 shares of common stock at $10.00 per share and pre-funded warrants to purchase 2,750,010 shares at $9.9999 per share. The company intends to use the net proceeds to fund the Phase 3 clinical trial for denifanstat, pre-launch activities, and general corporate purposes.…more
$9.75+1.93%vs prev closeView filingShare
16 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 20:00#●●●#●●●
Sagimet Biosciences Doses First Patient in Phase 3 Acne Trial
Sagimet Biosciences has initiated patient dosing for its Phase 3 clinical trial of denifanstat, a treatment for moderate to severe acne. The study aims to support a potential U.S. regulatory filing, with topline results expected in the second half of 2027.…more
$9.75+1.93%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.9Pre-market26.10.09 20:00
●●●●●●●● ●●●●● ●●●●●●
Sagimet announced positive 52-week safety and efficacy results from its partner Ascletis' Phase 3 trial of denifanstat for acne in China. These findings support the company's ongoing U.S. Phase 3 clinical program, although the drug has not yet received final regulatory approval in the U.S.…more
$9.75+1.93%vs prev close - 10.1After-hours26.10.02 05:31
●●●●●●●● ●●●●● ●●●●●●
Sagimet Biosciences has closed its underwritten offering of common stock and pre-funded warrants, raising approximately $115 million in gross proceeds. The company intends to use the funds to support Phase 3 clinical trials and general corporate purposes.…more
$9.75+1.93%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report